Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Asia Healthcare Industry Digest.
Press releases published on May 22, 2025
JUARA Skincare Announces Memorial Day Sale: 15% Off Sitewide from May 23 to 26
EIN Presswire
·
May 22, 2025
JUARA, a skincare brand rooted in traditional Indonesian beauty rituals, is offering a limited-time Memorial Day sale, running from May 23 to May 26. NEW YORK, NY, UNITED STATES, May 22, 2025 /EINPresswire.com/ -- JUARA, a skincare brand rooted in …
The Watermark at San Jose Celebrates Grand Opening
EIN Presswire
·
May 22, 2025
𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝘃𝗲 𝗹𝘂𝘅𝘂𝗿𝘆 𝘀𝗲𝗻𝗶𝗼𝗿 𝗰𝗼𝗺𝗺𝘂𝗻𝗶𝘁𝘆 𝗯𝗿𝗶𝗻𝗴𝘀 𝗻𝗲𝗶𝗴𝗵𝗯𝗼𝗿𝗵𝗼𝗼𝗱-𝗶𝗻𝘀𝗽𝗶𝗿𝗲𝗱 𝗹𝗶𝘃𝗶𝗻𝗴 𝗮𝗻𝗱 𝗰𝘂𝗹𝘁𝘂𝗿𝗮𝗹 𝗰𝗲𝗹𝗲𝗯𝗿𝗮𝘁𝗶𝗼𝗻 𝘁𝗼 𝘁𝗵𝗲 𝗵𝗲𝗮𝗿𝘁 𝗼𝗳 𝗦𝗶𝗹𝗶𝗰𝗼𝗻 𝗩𝗮𝗹𝗹𝗲𝘆 SAN JOSE, CA, UNITED STATES, May 22, 2025 /EINPresswire.com/ -- Watermark Retirement Communities and Alliance Residential …
UltraSight™ Appoints Peter Chang Soo Kim to Board of Directors
EIN Presswire
·
May 22, 2025
Global business leader brings 40+ years of leadership across insurance, healthcare, and institutional strategy BOSTON, MA, UNITED STATES, May 22, 2025 /EINPresswire.com/ -- UltraSight™, a digital health leader using machine learning to transform cardiac …
Junaid Family Foundation Signs Letter of Cooperation with Gates Foundation & UNICEF to Advance Maternal Health
EIN Presswire
·
May 22, 2025
JFF is proud to announce the signing of a landmark LoC with the Gates Foundation …
New Report Examines the Impact of Disinformation on Public Health Outcomes
EIN Presswire
·
May 22, 2025
MANILA, PHILIPPINES, May 22, 2025 /EINPresswire.com/ -- In an era of widespread access to information, the growing influence of disinformation presents complex challenges for public health. A new analysis, The Silent Threat: How Disinformation Harms …
China’s Version of Inspiren: Non-Intrusive, Wear-Free, Proactive Care for Aging at Home
EIN Presswire
·
May 22, 2025
BEIJING, CHINA, May 22, 2025 /EINPresswire.com/ -- The 11th China International Senior Service Industry Expo opened today at the Beijing International Convention Center, presided over by Zhang Meiy ing，Vice Chairwoman of the 11th National Committee of …
Soleno Therapeutics Announces Submission and EMA Validation of Marketing Authorization Application for Diazoxide Choline Prolonged-Release Tablets for the Treatment of Hyperphagia in Patients with Prader-Willi Syndrome
GlobeNewswire
·
May 22, 2025
REDWOOD CITY, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Soleno’s Marketing Authorization …
Iovance Announces Five-year Results of Amtagvi® (lifileucel) in Patients with Advanced Melanoma at ASCO Annual Meeting
GlobeNewswire
·
May 22, 2025
One-time Amtagvi Treatment Demonstrated Durable Responses and a Five-year Overall Survival Rate of 20% Five-year Follow Up is Unprecedented for Any Therapy in Patients with Advanced Melanoma Previously Treated with Immune Checkpoint Inhibitor SAN CARLOS, …
Merus’ Petosemtamab with Pembrolizumab Interim Data Demonstrates Robust Efficacy and Durability in 1L PD-L1+ r/m HNSCC
GlobeNewswire
·
May 22, 2025
- 63% response rate observed among 43 evaluable patients - 79% overall survival rate at 12-months; 9 months median progression-free survival - Conference Call on Thursday, May 22 at 5:30 p.m. ET UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 22, …
Kura Oncology and Kyowa Kirin Announce Pivotal Monotherapy Data for Ziftomenib in Oral Presentation at the 2025 ASCO Annual Meeting
GlobeNewswire
·
May 22, 2025
– Results from KOMET-001 registration-directed trial of ziftomenib in R/R NPM1-m AML patients selected for oral presentation on Monday, June 2nd – – Encore presentation planned at EHA 2025 Congress – – Kura Oncology to host virtual investor event at 7:30pm …
PDS Biotech Announces Positive Extended Follow-Up Data for VERSATILE-002 and Additional Trials Evaluating Versamune® HPV to be Presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewswire
·
May 22, 2025
Phase 2: Versamune® HPV with pembrolizumab as 1L treatment of r/m HPV16-positive HNSCC - Median overall survival for CPS ≥20 is 39.3 months - Median overall survival for CPS ≥1 is 30.0 months Phase 3: Versamune® HPV with pembrolizumab as 1L treatment of r/ …
IMUNON Announces Withdrawal of Form S-1 Registration Statement
GlobeNewswire
·
May 22, 2025
LAWRENCEVILLE, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that it has filed a request for withdrawal with the Securities and …
Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel
GlobeNewswire
·
May 22, 2025
SOUTH SAN FRANCISCO, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today …
ImCheck Reports High Remission Rates in AML Patients with ICT01 Combination Therapy at ASCO 2025
GlobeNewswire
·
May 22, 2025
ImCheck Reports High Remission Rates in AML Patients with ICT01 Combination Therapy at ASCO 2025 ICT01 in combination with azacitidine and venetoclax (Aza-Ven) achieves unprecedented high remission rates overall and across molecular subtypes in newly …
Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology to Present Positive Results from Pivotal Phase 2b REZILIENT1 Trial of Zipalertinib at ASCO 2025
GlobeNewswire
·
May 22, 2025
CAMBRIDGE, Mass. and TOKYO, Japan and PRINCETON, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), Taiho Pharmaceutical Co., Ltd., and Taiho Oncology, Inc. today announced new positive results from the pivotal Phase 2b …
Legend Biotech Announces New Oncologic & Hematologic Therapeutic Developments at ASCO, EHA, and ASGCT
GlobeNewswire
·
May 22, 2025
An oral presentation at ASCO …
Menarini Group Presents Updated Data Underscoring the Combinability of Elacestrant (ORSERDU®) in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the ASCO 2025 Annual Meeting
GlobeNewswire
·
May 22, 2025
Preliminary efficacy analysis from the elacestrant plus everolimus and ribociclib cohorts of the ELEVATE study, along with updated safety data from additional cohorts of elacestrant plus targeted therapy combination arms, will be presented. These data …
Chinese technology deal speeds up Pakistan's pharma production
EIN Presswire
·
May 22, 2025
SHEIKHUPURA, PAKISTAN, May 22, 2025 /EINPresswire.com/ -- Pharmaceutical machinery provider Xin Weisheng is streamlining Pakistan’s manufacturing of healthcare products with its unique processing equipment. Xin Weisheng technology is enabling …
Boehringer Ingelheim to present early clinical evidence of innate immune modulation and anti-tumor activity via SIRPα blockade in two ongoing trials at ASCO 2025
GlobeNewswire
·
May 22, 2025
· BI 765063 in combination with programmed cell death-1 (PD1) inhibitor antibody ezabenlimab + cetuximab demonstrated a well-tolerated safety profile and potentially promising efficacy signals as second-line treatment in patients with recurrent/ …
Actuate Therapeutics Announces Details for 2025 ASCO Annual Meeting Presentation on Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer
GlobeNewswire
·
May 22, 2025
Phase 2 (Actuate-1801 Part 3B) trial topline results meet primary endpoint of improved survival in previously untreated patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) Oral presentation at the American Society of Clinical Oncology (ASCO) …